Table 3 Summary of the follow-up of the thyroid nodule volume, patients’ symptoms, and the thyroid hormone level
From: Efficacy and safety of ultrasound (US)-guided radiofrequency ablation of benign thyroid nodules
Pretreatment | 1 month follow-up | 3 months’ follow-up | 6 months’ follow-up | Test value | P value | Sig. | ||
|---|---|---|---|---|---|---|---|---|
Thyroid profile | Euthyroidism | 38 (95.0%) | 40 (100.0%) | 40 (100.0%) | 40 (100.0%) | 6.076a | 0.108 | NS |
Hyperthyroidism | 2 (5.0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Compressive symptoms scoring (0–10) | Median (IQR) | 8 (6–9) | 4 (3–5) | 2 (1–3) | 0 (0–1) | 105.952b | 0.000 | HS |
Range | 4–10 | 2–7 | 0–5 | 0–3 | ||||
Cosmetic scoring (1–4) | Median (IQR) | 4 (3–4) | 2 (1.5–2) | 1 (1–2) | 1 (1–1) | 81.506b | 0.000 | HS |
Range | 2–4 | 1–4 | 1–4 | 1–4 | ||||
Volume of the nodule | Median (IQR) | 15 (8.5–39.5) | 5.5 (3.2–12) | 3.3 (1.9–6.8) | 2.2 (1.2–3.5) | 104.985b | 0.000 | HS |
Range | 0.5–245 | 0.3–118 | 0.1–96 | 0.1–30 | ||||
Volume reduction ratio (%) | Mean ± SD | – | 58.41 ± 15.27 | 73.26 ± 11.22 | 82.54 ± 12.49 | 92.900 | 0.000 | HS |
Range | – | 29.52–96.23 | 40–94.14 | 36–98.28 | ||||